Efficacy and safety of minimally invasive injection steam therapy for lower urinary tract symptoms caused by benign prostate hyperplasia (first clinical experience in the Russian Federation)
- Authors: Shibaev A.N.1,2,3, Podoynitsyn A.A.4,3, Suleymanov R.S.1, Pavlova Y.V.3, Bogatov D.V.1, Federyakin D.V.1, Ivkin E.V.5, Kozlova A.T.5, Kolontarev K.B.5,6, Govorov A.V.5,6, Pushkar D.Y.5,6
-
Affiliations:
- Tver State Medical University
- University Clinic of Tver State Medical University
- GBUZ Moscow district “Moscow Regional Research Clinical Institute named after M.F. Vladimirsky
- RTH Clinic
- S.P. Botkin’s State Clinical Hospital
- FGBOU VO “Russian University of Medicine”, Ministry of Health of the Russian Federation
- Issue: No 3 (2025)
- Pages: 15-21
- Section: Original Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/687824
- DOI: https://doi.org/10.18565/urology.2025.3.15-21
- ID: 687824
Cite item
Open Access
Access granted
Abstract
Introduction. Currently, the development of new methods of treatment of benign prostatic hyperplasia (BPH) is continuing, combining the high efficiency of transurethral resection of the prostate, which are safer for elderly patients and provide a high level of quality of life for younger patients. One of these new methods is minimally invasive water vapor thermal therapy.
Aim. To evaluate the efficiency and safety of water vapor thermal therapy in patients with lower urinary tract symptoms (LUTS)/BPH.
Materials and methods. A total of 35 patients with LUTS/BPH who were treated between September 2022 and September 2024 (median follow-up of 12 months) were included in the study. The average age was 68.7±1.5 years. The prostate volume did not exceed 80 cc (52.4±4.2 cc). The Qmax was 9.3±0.7 ml/sec. The postvoid residual volume (PVR) was 73.6±12.2 ml. The overall IPSS score was 26.5±2.3 and QoL was 4.3±0.3. All patients were treated with water vapor thermal therapy according to the standard procedure recommended by the manufacturer (5.7±0.72 injections of water vapor into the prostate). The efficacy was evaluated every 3 months after the procedure. Intra- and postoperative complications were assessed on Clavien-Dindo classification.
Results. After 3 months, 97.1% (34 out of 35) of patients had an improvement in objective urination parameters. Qmax and PVR after 3 months increased up to 17.3±1.5 ml/sec and 20.8±7.2 ml, respectively (p<0.05 compared with baseline values). There was also a significant decrease in IPSS and QoL levels, 8,5±1,3 and 2,3±0,3, respectively (p<0,05 compared with the baseline). Qmax and PVR continued to improve till the 6 months of follow-up (17.6±1.1ml/sec and 14.3±0.8 ml, respectively, p<0.05 compared with baseline and after 3 months). There was also a significant decrease in IPSS and QoL to 4.1±1.3 and 1.4±0.1 points, respectively (p<0.05 compared to 3 months). After that, these values remained stable throughout the follow-up period. The overall efficiency of the treatment (at median follow-up of 12 months) was 88,6%. Perioperative complications occurred in 9 out of 35 patients (did not exceed IIIa according to Clavien-Dindo).
Conclusions. Minimally invasive water vapor thermal therapy is a new effective and safe method of treating patients with LUTS/BPH. After the procedure, there is a significant improvement in lower urinary tract symptoms.
Full Text
About the authors
Andrey N. Shibaev
Tver State Medical University; Tver State Medical University; University Clinic of Tver State Medical University; GBUZ Moscow district “Moscow Regional Research Clinical Institute named after M.F. Vladimirsky
Email: anshibaev@rambler.ru
ORCID iD: 0000-0002-5568-3342
Ph.D., Head of the Department of Urology and Andrology of FGBOU VO Tver State Medical University of the Ministry of Health of Russia; University Clinic of Tver State Medical University; Leading researcher at the Department of Urology of GBUZ Moscow district “Moscow Regional Research Clinical Institute named after M.F. Vladimirsky
Russian Federation, 170100, Tver, Sovetskaya st., 4; 170100, Tver, Sovetskaya st., 4; 129110, Moscow, st. Shchepkina, 61/2Alexey A. Podoynitsyn
RTH Clinic; GBUZ Moscow district “Moscow Regional Research Clinical Institute named after M.F. Vladimirsky
Email: a4955145801@gmail.com
ORCID iD: 0000-0001-9739-6248
Ph.D., MD, Head of the Department of Urology of GBUZ Moscow district “Moscow Regional Research Clinical Institute named after M.F. Vladimirsky
Russian Federation, Moscow; 129110, Moscow, st. Shchepkina, 61/2Ruslan S. Suleymanov
Tver State Medical University
Email: rusuromed@gmail.com
ORCID iD: 0000-0002-0534-0472
urologist at the University Clinic
Russian Federation, 170100, Tver, Sovetskaya st., 4Yulia V. Pavlova
GBUZ Moscow district “Moscow Regional Research Clinical Institute named after M.F. Vladimirsky
Email: 9250659260@mail.ru
ORCID iD: 0000-0002-3042-8708
Ph.D., researcher at the Department of Urology
Russian Federation, 129110, Moscow, st. Shchepkina, 61/2Dmitry V. Bogatov
Tver State Medical University
Email: bogatov.d@yandex.ru
Ph.D., associate professor at the Department of Urology and Andrology of FGBOU VO Tver State Medical University of the Ministry of Health of Russia; University Clinic of Tver State Medical University
Russian Federation, 170100, Tver, Sovetskaya st., 4Denis V. Federyakin
Tver State Medical University
Email: denic_federiakin@mail.ru
Ph.D., MD, professor, Chief of the University Clinic
Russian Federation, 170100, Tver, Sovetskaya st., 4Evgeniy V. Ivkin
S.P. Botkin’s State Clinical Hospital
Email: e.ivkin@hotmail.com
ORCID iD: 0000-0003-4568-9561
Ph.D., urologist, oncologist, Moscow Urologic Center
Russian Federation, 125284, Moscow, 2nd Botkinsky proezd, 5Anna T. Kozlova
S.P. Botkin’s State Clinical Hospital
Author for correspondence.
Email: k.a.timofeevna@mail.ru
urologist, Moscow Urologic Center
Russian Federation, 125284, Moscow, 2nd Botkinsky proezd, 5Konstantin B. Kolontarev
S.P. Botkin’s State Clinical Hospital; FGBOU VO “Russian University of Medicine”, Ministry of Health of the Russian Federation
Email: kb80@yandex.ru
ORCID iD: 0000-0003-4511-5998
Deputy Chief of the Moscow Urological Center of S.P. Botkin City Clinical Hospital; Ph.D., MD, professor at the Department of Urology of Scientific and Educational Institute of the Clinical Medicine named after N.A. Semashko; FGBOU VO “Russian University of Medicine”
Russian Federation, 125284, Moscow, 2nd Botkinsky proezd, 5; MoscowAlexander V. Govorov
S.P. Botkin’s State Clinical Hospital; FGBOU VO “Russian University of Medicine”, Ministry of Health of the Russian Federation
Email: dr.govorov@gmail.com
ORCID iD: 0000-0003-3299-0574
urologist at the Moscow Urological Center of S.P. Botkin City Clinical Hospital; Ph.D., MD, professor of the RAS, professor at the Department of Urology of Scientific and Educational Institute of the Clinical Medicine named after N.A. Semashko; FGBOU VO “Russian University of Medicine”
Russian Federation, 125284, Moscow, 2nd Botkinsky proezd, 5; MoscowDmitry Yu. Pushkar
S.P. Botkin’s State Clinical Hospital; FGBOU VO “Russian University of Medicine”, Ministry of Health of the Russian Federation
Email: pushkardm@mail.ru
ORCID iD: 0000-0002-6096-5723
academician of RAS, Ph.D., MD, Professor, Chief urologist of the Ministry of Health of Russia, Chief urologist of the Moscow Health Department, Chief of Moscow Urological Center of S.P. Botkin City Clinical Hospital, Head of the Department of Urology of FGBOU VO “Russian University of Medicine”
Russian Federation, 125284, Moscow, 2nd Botkinsky proezd, 5; MoscowReferences
- Verhamme KM, Dieleman JP, Bleumink GS et al. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol. 2003;44:539–45. doi: 10.1016/s0302-2838(03)00376-2
- Cindolo L, Pirozzi L, Fanizza C et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. EurUrol. 2015;68:418. doi: 10.1016/j.eururo.2014.11.006.
- Lopategui DM, Shah HN, Herrmann TRW. Antegrade ejaculation preservation in surgical treatment for benign prostatic hyperplasia: quest for balance between voiding and sexual function. Curr Opin Urol. 2024;34(4):286–293. doi: 10.1097/MOU.0000000000001178.
- Mynderse LA, Hanson D, Robb RA et al. Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. 2015;86:122. doi: 10.1016/j.urology.2015.03.021.
- Dixon C, Cedano ER, Pacik D et al. Efficacy and safety of Rezūm system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2015;86(5):1042–47. doi: 10.1016/j.urology.2015.05.046.
- McVary KT, Gange SN, Gittelman MC et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529–38. doi: 10.1016/j.juro.2015.10.181.
- Dixon C, Cedano V. et al. 631 Transurethral water vapor therapy for BPH; initial clinical results of the first in man trial and Rezum™ I pilot study. European Urology Supplements. 2013;12(1):e631. doi: 10.1016/S1569-9056(13)61114-8.
- Sandhu JS, Bixler BR, Dahm P et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023. J Urol. 2023. doi: 10.1097/JU.0000000000003698
- McVary KT, Rogers T, Mahon J, Gupta NK. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J Sex Med. 2018;15(12):1728–38. doi: 10.1016/j.jsxm.2018.10.006.
- El-assmy A, Elshal AM, Mekkawy R, El-kappany H, Ibrahiem EHI. Erectile and ejaculatory functions changes following bipolar versus monopolar transurethral resection of the prostate: a prospective randomized study. Int Urol Nephrol. 2018;50(9):1569–76. doi: 10.1007/s11255-018-1950-6.
Supplementary files
